Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18633063 | COMPOSITIONS OF HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHODS OF PURIFYING THE SAME | April 2024 | September 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18633087 | COMPOSITIONS OF HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHODS OF PURIFYING THE SAME | April 2024 | November 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18384643 | COMPOSITIONS OF HYDROXYPROPYL-BETA-CYCLODEXTRIN AND METHODS OF PURIFYING THE SAME | October 2023 | April 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18077533 | REGULATED DRUG DELIVERY VIA CONTROLLED DEGRADABLE CHONDROITIN SULFATE PARTICLES | December 2022 | August 2024 | Allow | 21 | 2 | 1 | Yes | No |
| 17966388 | COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE AND THALASSEMIA | October 2022 | October 2024 | Abandon | 25 | 2 | 0 | No | No |
| 17890754 | METHOD FOR PREVENTING ENTRY AND REPLICATION OF ENVELOPED VIRUSES | August 2022 | October 2024 | Abandon | 26 | 2 | 0 | No | No |
| 17855430 | Composition for Promoting Restful Sleep and Methods of Making and Using the Same | June 2022 | September 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17718981 | OMEGA-ALICYCLIC TUNICAMYCINS AND ANALOGS | April 2022 | September 2024 | Allow | 29 | 3 | 0 | Yes | No |
| 17433520 | EXTERNAL PREPARATION FOR TREATING A VASCULAR ANOMALY | August 2021 | November 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17429531 | ANTITUMOR COMPOSITION | August 2021 | September 2024 | Allow | 38 | 1 | 0 | Yes | No |
| 17428883 | METHOD OF TREATMENT AND PHARMACEUTICAL DOSAGE FORM | August 2021 | November 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17426301 | OXEXIN 1 RECEPTOR ANTAGONISTS | July 2021 | October 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17423186 | PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF IN PREVENTION AND TREATMENT OF PROTEIN KINASE-RELATED DISEASE | July 2021 | October 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17421546 | COMBINATION IN THE TREATMENT OF NONTUBERCULOUS MYCOBACTERIAL DISEASES | July 2021 | October 2024 | Allow | 39 | 1 | 0 | Yes | No |
| 17418067 | METHODS FOR FORMING POLYPLEXES | June 2021 | November 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17299515 | AROMATIC RING DERIVATIVE AS IMMUNOREGULATION AND PREPARATION METHOD AND APPLICATION OF AROMATIC RING DERIVATIVE | June 2021 | September 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17284838 | ENZYMATIC PRODUCTION OF TAGATOSE | April 2021 | November 2024 | Allow | 43 | 2 | 0 | No | No |
| 17207250 | INHALATION AND TOPICAL USE OF A FORMULATION CONTAINING CYCLODEXTRIN, QUERCETIN AND ZINC, TO MITIGATE INFECTION BY ENVELOPED VIRUSES, SUCH AS HIV AND SARS-COV-2 | March 2021 | November 2024 | Abandon | 44 | 2 | 0 | Yes | No |
| 17270397 | IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS | February 2021 | January 2025 | Abandon | 47 | 2 | 0 | Yes | No |
| 17268107 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | February 2021 | June 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17267110 | TRANSGLUTAMINASE 2 (TG2) INHIBITORS | February 2021 | June 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17116016 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | December 2020 | July 2024 | Allow | 43 | 1 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner CREWS, JARET JAMES works in Art Unit 1693 and has examined 14 patent applications in our dataset. With an allowance rate of 64.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner CREWS, JARET JAMES's allowance rate of 64.3% places them in the 25% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CREWS, JARET JAMES receive 1.21 office actions before reaching final disposition. This places the examiner in the 15% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by CREWS, JARET JAMES is 40 months. This places the examiner in the 23% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +55.0% benefit to allowance rate for applications examined by CREWS, JARET JAMES. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 4% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.